Microbiology, Immunology & Molecular Genetics | Faculty | Adjunct Faculty | Jose L. Lopez-Ribot, Ph.D.


Microbiology, Immunology & Molecular Genetics Adjunct Faculty

  Research | More on Jose L. Lopez-Ribot

Jose L. Lopez-Ribot, Pharm.D./Ph.D.

Department of Biology,
University of Texas San Antonio
(UTHSCSA, School of Medicine, Microbiology, Immunology & Molecular Genetics)

Tel: (210) 458-7022
Fax: (210) 458-7023
Email: :jose.lopezribot@utsa.edu


Personal Statement

Dr. Lopez-Ribot has over 25 years of educational and research experience in the field of Microbiology and more specifically, Medical Mycology. He leads the graduate educational component of the DoD funded "Center of Excellence in Infection Genomics," with the overall goal of increasing the number of graduates, including underrepresented minorities, within the fields of molecular Microbiology & Immunology. He also serves as mentor/preceptor in the MBRS/RISE and MARC-USTAR graduate and undergraduate research programs to increase the number of underrepresented students in the biomedical sciences. He has served as chair of the Doctoral Studies Committee of the Cellular and Molecular Biology Ph.D. program. Most recently he developed the new Molecular Microbiology and Immunology track within the PhD program in Cellular and Molecular Biology, and also contributed to the development of the new BS degree in Microbiology and Immunology at the University of Texas San Antonio as well as the PhD program in Translational Medicine, established jointly between Immunology at UTSA and UTHSCSA. During his academic career, Dr. Lopez-Ribot has served as a mentor for over 25 graduate students, postdoctoral fellows, and visiting scientists. He has also served in over 75 thesis dissertation and graduate exam committees.


Ph.D., Pharmacy/Microbiology at the University of Valencia, Valencia, Spain


Keywords: Candida albicans

Research interests:
Dr. Lopez-Ribot's lab studies the immunopathogenesis of fungal infections, with an emphasis on the opportunistic pathogenic fungus Candida albicans. Some of the highlights of this research program include: a) development of novel immune-based therapies to combat candidiasis, b) the role of morphogenetic conversions in the pathogenesis of candidiasis, c) the study of C. albicans biofilms, and d) and high throughput screening for antifungal drug discovery. Other areas of interest include genomics and proteomics, cell wall and adhesion, antifungal drug resistance and development of diagnostic techniques for candidiasis. The main projects in the lab currently deal with targeting virulence factors, more specifically filamentation and biofilm formation, for the development of novel antifungal agents, and with developing microbial chips as a new universal technology platform for microbial culture at the nanoscale level

Awards & Accomplishments

  • NIH FIRST Award, 1997
  • Burroughs Wellcome Fund New Investigator in Molecular Pathogenic Mycology 2001
  • President’s Distinguished Achievement Award in Research 2011

Professional Affiliations

  • American Society for Microbiology (ASM)
  • Texas Branch of the ASM,
  • Medical Mycological Society of the Americas (MMSA); President 2012-13,
  • Association Española de Micologia (AEM), Seccion de Micologia Medica de la AEM,
  • European Confederation of Medical Mycology (ECMM),
  • Texas Faculty Association (TFA),
  • American Association of University Professors (AAUP)



Complete List of Publications

  • Uppuluri, P., A.K. Chaturvedi, A. Srinivasan, M. Banerjee, A.K. Ramasubramaniam, J.R. Köhler, D. Kadosh and J.L. Lopez Ribot. 2010. Dispersion as an Important Step in the Candida albicans Biofilm Developmental Cycle. PLoS Pathogens.6:e1000828
  • Uppuluri, P., A. Srinivasan, A.K. Ramasubramanian and J.L. Lopez-Ribot. 2011. Effect of fluconazole, amphotericin B and caspofungin against Candida albicans biofilms under conditions of flow and on biofilm dispersion. Antimicrob. Agents Chemother. 55:3591-3
  • Robbins, N., P. Uppuluri, J. Nett, R. Rajendran, G. Ramage, J.L. Lopez-Ribot, D. Andes, and L. E. Cowen. 2011. Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens. 7(9): e1002257. doi:10.1371/journal.ppat.1002257.
  • Uppuluri, P., AK Chaturvedi, N. Jani, R. Pukkila-Worley, C. Monteagudo, E. Mylonakis, J.R. Köhler and J.L. Lopez Ribot. 2012. Physiologic Expression of the Candida albicans Pescadillo Homolog Is Required for Virulence in the Murine Model of Hematogenously Disseminated Candidiasis. Eukaryot Cell. 11:1552-1556
  • Siles, S., A. Srinivasan, C.G. Pierce, J.L. Lopez-Ribot, and A.K. Ramasubramanian. 2013. High-throughput screening of a collection of known pharmacologically active small compounds for the identification of Candida albicans biofilm inhibitors. Antimicrob. Agents Chemother. 57:3681-7
  • Srinivasan, A., K.P. Leung, J.L. Lopez-Ribot, and A.K. Ramasubramanian. 2013. High-throughput nano-biofilm microarray for antifungal drug discovery. mBio. 4: e00331-13
  • Pierce, C.G. and J.L. Lopez-Ribot. 2013. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opinion on Drug Discovery. 8:1117-26
  • Pierce, C.G., A. Srinivasan, A., P. Uppuluri, A. K. Ramasubramanian and J.L. Lopez-Ribot. 2013. Antifungal therapy with an emphasis on biofilms. Current Opinion Pharmacology. 5: 726-30.
  • Kadosh, D. and J.L. Lopez-Ribot. 2013. Candida albicans: adapting to succeed. Cell Host and Microbe. 14:483-5
  • Sarkar, S., P. Uppuluri, C.G. Pierce and J.L. Lopez-Ribot. 2014. An in vitro study of sequential fluconazole/caspofungin treatment against Candida albicans biofilms. Antimicrob. Agents Chemother. 58: 1183-6

    Updated 05.17.2016